[en] The debate over whether to use age-adapted or age-independent estimated glomerular filtration rate (eGFR) cut-offs for diagnosing chronic kidney disease (CKD) reflects a fundamental tension between physiological understanding and clinical pragmatism. Age-adapted proponents highlight robust evidence that GFR declines naturally with age, with many healthy older adults falling below the traditional 60 ml/min/1.73 m2 threshold. They argue that fixed cut-offs risk overdiagnosing CKD in the elderly, potentially leading to unnecessary anxiety and treatment, while underrecognizing risk in younger individuals whose GFRs are abnormal for their age. Physiological and longitudinal studies support this view, suggesting age-specific percentiles may better reflect true pathology. Conversely, advocates for age-independent thresholds emphasize that age-related GFR decline is not benign. Large epidemiological studies show that older adults with an eGFR of 45-59 ml/min/1.73 m2 are at increased risk of kidney failure, cardiovascular events and mortality, even in the absence of albuminuria. They caution that redefining CKD based on age could exclude high-risk older adults from beneficial therapies and research and that 'healthy' reference populations may harbour undiagnosed disease. A balanced approach recognizes the physiological realities of aging while not ignoring the clinical risks associated with reduced kidney function in older adults. Individualized risk prediction tools and shared decision-making can help tailor diagnosis and management. Ultimately, moving beyond arbitrary thresholds toward a patient-centred, risk-based strategy may best serve individuals across their lifespans, ensuring that CKD diagnosis and care are both scientifically sound and clinically meaningful.
Disciplines :
Urology & nephrology
Author, co-author :
Delanaye, Pierre ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie ; Department of Nephrology-Dialysis-Apheresis, Hôpital Universitaire Carémeau, Université de Montpellier, Nîmes, France
Vart, Priya ; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Floege, Jürgen; Division of Nephrology, University Hospital, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Aachen, Germany
Zoccali, Carmine; Renal Research Institute, New York, NY, USA ; Institute of Molecular Biology and Genetics (Biogem), Ariano Irpino, Italy ; Associazione Ipertensione Nefrologia Trapianto Renale (IPNET), c/o Nefrologia, Grande Ospedale Metropolitano, Reggio Calabria, Italy
Language :
English
Title :
Age-adapted versus age-independent eGFR thresholds to diagnose CKD: integrating the debate and charting a balanced path forward.
Delanaye P, Jager KJ, Bökenkamp A et al. CKD: a call for an age-adapted definition. J Am Soc Nephrol 2019;30:1785–805. 10.1681/ASN.2019030238
Astley ME, Chesnaye NC, Hallan S et al. Age- and sex-specific reference values of estimated glomerular filtration rate for European adults Kidney Int 2025;107:1076–87. 10.1016/j.kint.2025.02.025
Melsom T, Norvik JV, Enoksen IT et al. Sex differences in age-related loss of kidney function. J Am Soc Nephrol 2022;33:1891–902. 10.1681/ASN.2022030323
Denic A, Mathew J, Lerman LO et al. Single-nephron glomerular filtration rate in healthy adults. N Engl J Med 2017;376:2349–57. 10.1056/NEJMoa1614329
Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024;105(4S): S1–314.
Liu P, Quinn RR, Lam NN et al. Accounting for age in the definition of chronic kidney disease. JAMA Intern Med 2021;181:1359–66. 10.1001/jamainternmed.2021.4813
Grams ME, Coresh J, Matsushita K et al. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis. JAMA 2023;330:1266–77.
Pottel H, Björk J, Rule AD et al. Cystatin C–based equation to estimate GFR without the inclusion of race and sex. N Engl J Med 2023;388:333–43. 10.1056/NEJMoa2203769
Rule AD, Glassock RJ. Cystatin C and the misdiagnosis of CKD in older adults. Nat Rev Nephrol 2024;20:560–1. 10.1038/s41581-024-00852-y
EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388:117–27.
Hallan SI, Matsushita K, Sang Y et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012;308:2349–60. 10.1001/jama.2012.16817
Grams ME, Brunskill NJ, Ballew SH et al. The Kidney Failure Risk Equation: evaluation of novel input variables including eGFR estimated using the CKD-EPI 2021 equation in 59 cohorts. J Am Soc Nephrol 2023;34:482–94. 10.1681/ASN.0000000000000050